Abstract
Background
Type 1 diabetes is believed to be an autoimmune condition, characterized by destruction of insulin-producing cells, due to the detrimental inflammation in pancreas. Growing evidences have indicated the important role of type I interferon in the development of type 1 diabetes.
Methods
Trex1-deficient rats were generated by using CRISPR-Cas9. The fasting blood glucose level of rat was measured by a Roche Accuchek blood glucose monitor. The levels of insulin, islet autoantibodies, and interferon-β were measured using enzyme-linked immunosorbent assay. The inflammatory genes were detected by quantitative PCR and RNA-seq. Hematein-eosin staining was used to detect the pathological changes in pancreas, eye and kidney. The pathological features of kidney were also detected by Masson trichrome and periodic acid-Schiff staining. The distribution of islet cells, immune cells or ssDNA in pancreas was analyzed by immunofluorescent staining.
Results
In this study, we established a Trex1-deletion Sprague Dawley rat model, and unexpectedly, we found that the Trex1−/− rats spontaneously develop type 1 diabetes. Similar to human diabetes, the hyperglycemia in rats is accompanied by diabetic complications such as diabetic nephropathy and cataract. Mechanistical investigation revealed the accumulation of ssDNA and the excessive production of proinflammatory cytokines, including IFN-β, in Trex1 null pancreas. These are likely contributing to the inflammation in pancreas and eventually leading to the decline of pancreatic β cells.
Conclusions
Our study links the DNA-induced chronic inflammation to the pathogenesis of type 1 diabetes, and also provides an animal model for type 1 diabetes studies.
Similar content being viewed by others
Background
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the destruction of pancreatic β-cells, resulting in impaired insulin secretion and high levels of blood glucose. Genetic susceptibility and environmental factors, like virus infections and diet, have been implicated in the development of T1D [1,2,3]. Currently, it is believed that the destruction of β cells in T1D results from combined actions of both innate and adaptive immune cells [4,5,6]. And emerging evidences have shown that type I interferon (IFN), as a crucial factor in both innate immunity and adaptive immunity, plays a key role in the development of T1D [7, 8].
Animal models, especially mice and rats, play an essential role in the studies of pathogenesis and treatment of T1D. These models include the spontaneous models like Non-Obese Diabetic (NOD) mice and BioBreeding (BB) rats [9,10,11], as well as induced models such as streptozotocin (STZ)-induced diabetes model and alloxan-induced diabetes model [12, 13]. Employment of these models in T1D research has provided important insights into the development of this disease. However, a better model that presents autoimmune-related pathogenesis and exhibits more comprehensive disease-associated manifestations is still necessary.
Three Prime Repair Exonuclease 1 (TREX1) is a DNA exonuclease that functions in the degradation of cytosolic DNA [14, 15]. The absence or dysfunction of TREX1 thus leads to the accumulation of cytosolic DNA, which in turn activates the cytosolic DNA sensor, cyclic GMP-AMP synthase (cGAS), and promote the expression of type I IFN and other proinflammatory cytokines through signal transduction cascade [16, 17]. Hence, deficiency of TREX1 results in sustained activation of cGAS-mediated immune responses which eventually leads to tissue inflammation and damage. Mutations in TREX1 are associated with the development of several autoimmune diseases, including Aicardi-Goutières Syndrome (AGS) [18], systemic lupus erythematosus (SLE) [19], familial chilblain lupus (FCL) [20], and retinal vasculopathy with cerebral leukodystrophy (RVCL) [21]. In this study, we found that deficiency of Trex1 in rats leads to spontaneous development of T1D, accompanied by complications such as diabetic cataract and diabetic nephropathy. Mechanistically, Trex1 deficiency results in the accumulation of single-stranded DNAs (ssDNAs) and excessive production of type I IFN. Thus, our study provides a potential animal model for T1D researches, and may offer new insight into the pathogenesis of T1D.
Methods
Rat
Wild-type and Trex1−/− Sprague Dawley (SD) rats were obtained from Nanjing Biomedical Research Institute of Nanjing University based on CRISPR-Cas9 technology. The guide RNA sequence is as follows: 5′-GTCCACCACACGGGGTGGTT-3′. All rats were housed on a 12 h light/dark cycle with ad libitum access to food and water. All animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and with the approval of the Institutional Animal Care and Use Committee of the National Center of Biomedical Analysis (IACUC-DWZX—2021-768). WT and Trex1−/− rats were littermates obtained from heterozygous breeding. Rats were randomly allocated into different groups according to their genotype, and the number of rats were not subjectively reduced or excluded.
Diabetes assessment and STZ model
Blood glucose levels were measured by a Roche Accuchek blood glucose monitor. Rats were considered as diabetic after two consecutive blood glucose measurements over 13.8 mmol/L. For observation of diabetic phenotypes experiments in Fig. 1A, WT (n = 32; female, n = 20; male, n = 12) and Trex1−/− (n = 46; female, n = 26; male, n = 20) rats were monitored for one year, with the measurements conducted at a frequency of once a month. For STZ experiments, adult male SD rats (body weight 250–300 g) were fasted for 12–16 h and then treated with a single dose of streptozotocin (STZ, 30 mg/kg of body weight, Sigma-Aldrich, V900890) intraperitoneally. Blood glucose was measured every 3 days post injection.
Glucose tolerance test and insulin tolerance test
For glucose tolerance test (GTT), rats were fasted for 12–16 h prior to the injection of glucose (2 g/kg of body weight) intraperitoneally. Blood glucose levels were assessed at 0, 15, 30, 60, 90 and 120 min post injection. WT (n = 10; female, n = 4, body weight 259 ± 16 g; male, n = 6, body weight 422 ± 21 g) and Trex1−/− (n = 10; female, n = 6, body weight 244 ± 15 g; male, n = 4, body weight 377 ± 84 g) rats were used in this experiment. For insulin tolerance test (ITT), rats were fasted for 4 h and received an intraperitoneal injection of insulin (1 U/kg of body weight, MedChemExpress, HY-P0035). Blood glucose levels were evaluated at 0, 15, 30, 60, 90 and 120 min following insulin administration. WT (n = 9; female, n = 3, body weight 287 ± 8 g; male, n = 6, body weight 478 ± 21 g) and Trex1−/− (n = 10; female, n = 7, body weight 270 ± 22 g; male, n = 3, body weight 433 ± 22 g) rats were detected in this experiment.
Histological staining
Tissues of pancreas, kidney or eye from rats were fixed with 4% paraformaldehyde for 24–48 h, dehydrated and embedded in paraffin, and subsequently sectioned serially at 4 μm. Paraffin sections were stained using Hematoxylin–Eosin Stain Kit (Solarbio, G1120). PAS and Masson’s trichrome staining of kidney sections were performed by Beijing Xuebang Technology Co., Ltd and Wuhan Servicebio Technology Co., Ltd. All images were obtained using NanoZoomer 2.0 (HAMAMATSU).
Insulitis scoring
H&E-stained pancreatic sections were scored blindly for islet inflammation. Insulitis scoring was performed as previously described [22]. Scoring was as follows: “non-insulitis” indicates no inflammatory cells infiltration; “peri-insulitis” indicates that inflammatory cells surround around the pancreatic islets and with less than 25% area of islets being impaired; “non-aggressive insulitis” refers to 25–50% area of pancreatic islets infiltrated with inflammatory cells; “aggressive insulitis” refers to almost destroyed islets with or without residual inflammatory cells.
Immunofluorescence
Paraffin embedded tissue sections were blocked with 5% normal goat serum for 1 h, and then incubated overnight at 4 °C with primary antibodies as follows: anti-Insulin (1:100, Abcam, ab7842), anti-Glucagon (1:150, Cell Signaling Technology, 2760S), anti-CD8 (1:100, Bio-Rad, MCA48GA), anti-CD68 (1:100, Bio-Rad, MCA341GA), anti-DNA (1:20, Millipore, single stranded specific, MAB3299). Secondary antibodies were employed as follows: Alexa Fluor 488 (1:400, Jackson ImmunoResearch or Thermo Fisher Scientific) and Alexa Fluor 594 (1:400, Thermo Fisher Scientific). Nuclei were stained with Hoechst (1:1000, Thermo Fisher Scientific, H3570). Images were acquired via ZEISS LSM 880 confocal microscope, and data collection was performed using ZEN 2.1 SP2 Black version 13.0.2.518 (ZEISS). The statistical analysis of fluorescent images was performed independently and blindly by two individuals.
RNA extraction and quantitative PCR
Pancreas tissues were lysed through liquid nitrogen grinding rapidly. And total RNA was then isolated using TRI reagent (Sigma, T9424). RNA was reversed into cDNA by Prime Script RT Master Mix (Takara, RR036A). Quantitative PCR (qPCR) was performed with SYBR Green Master Mix (Thermo Fisher Scientific, A25778) on Applied Biosystems QuantStudio 3/5 Real-Time PCR System (Applied Biosystems). Relative expression of tested genes was normalized to housekeeping gene Gapdh and control samples through the 2−ΔΔCt method. Primer sequences used in this study are provided in Additional file 1: Table S1.
RNA-seq
Briefly, total RNA was isolated from the pancreas of WT or Trex1−/− rats and the integrity of RNA was determined on an Agilent 2100 bioanalyzer. The transcriptome library was then constructed and sequenced via the Illumina sequencing platform (pair-end 150 bp) of Annoroad Gene Technology (Shanghai, China). Sequencing reads were aligned to RN6 using HISAT2 and differentially expressed genes (DEGs, adjusted P < 0.05 and fold change > 2 or fold change < 0.5) were identified with DESeq2. The up-regulated differentially expressed genes in RNA-seq data were analyzed and fold change of indicated ISGs and pro inflammatory cytokines were shown.
ELISA
Serum insulin, GADA, IAA, ICA and IFN-β were measured using Rat/mouse insulin ELISA Kit (Millipore, EZRMI-13K), Rat GAD-Ab ELISA Kit (Shanghai Jiang Lai, JL11155), Rat IAA ELISA Kit (Shanghai Jiang Lai, JL10558), Rat ICA ELISA Kit (Shanghai Jiang Lai, JL10634) and Rat Interferon Beta (IFNβ) ELISA Kit (Shanghai Jiang Lai, JL20851), respectively. These assays were performed according to manufacturer’s instructions.
Biochemical assays
Serum of WT or Trex1−/− rats was collected and the levels of HbA1c, urea and creatinine in serum were analyzed by Beijing BJ•XinChuangYuan BIOTECH CO., LTD. (China). 24-h urine from each rat was collected with a metabolic cage. Urinary albumin and creatinine were analyzed by Beijing BJ•XinChuangYuan BIOTECH CO., LTD. (China).
Cataract grading
Using a slit lamp, the dilated pupils were examined regularly. According to the turbidity of lens, cataracts were graded into 6 stages by two experienced ophthalmologists. Stage 0: The lens is transparent. Stage 1: Cataract with a slight degree of punctate opacification. Stage 2: Cataract with an enlarged punctate opacification, which occupy 1/4 of the lens. Stage 3: Wheel-like turbidity over two quadrants. Stage 4: Wheel-like turbidity over three quadrants. Stage 5: The entire lens is turbid.
Statistical analysis
The statistical analysis and sample sizes are descripted in the figure legends. The statistics were performed using GraphPad Prism (GraphPad Software). Briefly, the Shapiro–Wilk test and F test was employed to test normality and homogeneity of variance, respectively. For data of two groups that meet the normal distribution, unpaired t-test or Welch’s t test was applied; While the data do not meet the normal distribution, we used Mann–Whitney test. Multiple comparisons were carried out by Two-way ANOVA, and Log-rank (Mantel-Cox) test was used in the survival analysis. P values are shown in the figures. Data are shown as mean ± SEM.
Results
Trex1-deficient rats develop spontaneous diabetes
We generated Trex1-deficient Sprague Dawley (SD) rats by deleting 122 base pairs in exon 2 of Trex1 gene using CRISPR-Cas9 (Additional file 2: Fig. S1A–C). Unexpectedly, we noticed that the Trex1−/− rats displayed diabetic-like symptoms, including polydipsia (increased thirst) and polyphagia (increased appetite) (Additional file 2: Fig. S1D). To further investigate this phenomenon, we performed a long-term monitoring of fasting blood glucose in wild-type (WT) and Trex1−/− rats, starting from 4 weeks of age, with a frequency of once a month, lasting for 1 years. We found that Trex1−/− rats exhibited evidently elevated blood glucose compared to WT rats (Fig. 1A). According to the diagnostic criteria for diabetes, we considered the blood glucose level over 13.8 mmol/L for two consecutive measurements as diabetic [22,23,24]. The prevalence of diabetes in Trex1−/− rats progressively increased with age, and approximately 70% of both male and female rats developed diabetes by 48 weeks of age (Fig. 1B, Additional file 2: Fig. S1E). Additionally, we observed that Trex1−/− rats had a higher hemoglobin A1c (HbA1c) than WT rats, and the glucose tolerance in Trex1−/− rats was also impaired, supporting that Trex1−/− rats are deficient in glycemic control (Fig. 1C–E). Furthermore, compared to WT rats, the lifespan of Trex1−/− rats was shortened after onset of diabetes (Fig. 1F). Thus, these data suggest that Trex1−/− rats spontaneously develop diabetes.
Streptozotocin (STZ) is widely utilized in chemically induced diabetes model for preclinical diabetes research [25,26,27]. We next treated WT and Trex1−/− rats with a single low-dose STZ (30 mg/kg), a dose of which is insufficient to induce diabetes in WT rats. Following STZ treatment, Trex1−/− rats exhibited an earlier onset and higher incidence of diabetes (Fig. 1,G, H), indicating the increased susceptibility to STZ-induced diabetes in Trex1−/− rats.
Trex1-deficient rats develop type 1 diabetes
To elucidate the role of TREX1 in spontaneous development of diabetes, we first examined the type of diabetes that Trex1−/− developed. Generally, T1D results from destruction of pancreatic β-cells, which causes defective secretion of insulin, while Type 2 diabetes arises from insulin resistance [28,29,30]. We then measured the fasting insulin in serum, and found that Trex1−/− rats exhibited apparently deficient, even absent, insulin secretion (Fig. 2A). Meanwhile, insulin tolerance test showed no significant difference in blood glucose changes between WT and Trex1−/− rats (Fig. 2B). The presence of autoantibodies in serum is an important indicator of T1D, including glutamic acid decarboxylase autoantibodies (GADA), insulin autoantibodies (IAA) and islet cell antibodies (ICA). We found that serum levels of the above-mentioned autoantibodies were significantly elevated in Trex1−/− rats when compared to those in WT rats (Fig. 2C, Additional file 3: Fig. S2A). These results demonstrated that Trex1−/− rats manifested T1D-like characteristics. We next verified the morphology and integrity of islets in Trex1−/− rats. Hematoxylin and eosin (H&E) staining was performed and showed that the pancreatic islets were damaged in Trex1−/− rats, accompanied by infiltration of immune cells (Fig. 2D). Furthermore, we observed remarkable loss of β-cells in pancreatic islets of Trex1−/− rats, while their α-cells had little difference compared to WT rats (Fig. 2E, F). Taken together, these data suggest that Trex1-deficient rats develop T1D.
Trex1-deficient rats exhibit insulitis and infiltration of immune cells
The development of T1D is usually associated with insulitis triggered by infiltrated immune cells and local inflammation [31,32,33]. As the above H&E data suggested that pancreatic islets were infiltrated by immune cells in Trex1−/− rats, we further confirmed this phenomenon using pancreatic sections adopted from both 8- and 24-week WT and Trex1−/− rats. Histological analysis revealed that Trex1−/− rats appeared varying degrees of insulitis with age, and the incidence and severity of which showed a notable increase at 24 weeks of age (Fig. 3A, B and Additional file 3: Fig. S2B). We also observed considerable infiltration of CD8-positive T-cells and CD68-positive macrophages in pancreatic islets of Trex1−/− rats, compared to those in WT rats (Fig. 3C–F). Besides, we detected up-regulated expression of pro-inflammatory cytokines, such as Tnf, Il1b, Ifng, Cxcl9 and Cxcl10 in the pancreas of Trex1−/− rats (Fig. 3G). Thus, these data suggest that deficiency of Trex1 induces infiltration of immune cells into pancreatic islets which may create an inflammatory environment.
Trex1 deficiency results in accumulation of ssDNA and elevated production of IFN-β in pancreas
Previous works have revealed that TREX1 deficiency is implicated in the development of several autoimmune diseases, mechanistically through the sustained activation of type I IFN pathway induced by aberrant accumulation of DNA [17, 34, 35]. We therefore speculated that the insulitis observed in Trex1−/− rats might be attributed to the aberrant activation of IFN signaling in pancreatic islets. To prove this, we first detect the production of type I IFN in Trex1−/− rats, and observed an obvious increase of IFN-β in the serum of Trex1−/− rats (Fig. 4A). Interferon-stimulated genes (ISGs), including Rsad2, Isg15, Ifit1 and Mx1, also showed enhanced expression in the pancreas obtained from Trex1−/− rats (Fig. 4B). Moreover, immuno-staining of ssDNA with β-cell marker revealed substantially accumulated ssDNA around the islet β cells of Trex1−/− rats, indicating that the activation of IFN signaling in Trex1−/− rats is possibly induced by the accumulation of ssDNA in pancreatic islets (Fig. 4C, D). We next performed an RNA-seq using the pancreas tissue of WT and Trex1−/− rats, and identified 598 differentially expressed genes (335 up-regulated and 263 down-regulated, fold change > 2, P value < 0.05) (Additional file 4: Fig. S3A, B). Among the down-regulated genes, KEGG analysis uncovered notable enrichment of terms associated with insulin secretion (Additional file 4: Fig. S3C), supporting the T1D phenotype observed in Trex1−/− rats (Fig. 2). We also analyzed the up-regulated differentially expressed genes in RNA-seq data. Compared to WT rats, we found elevated expression of a number of ISGs (Fig. 4E), as well as a series of pro-inflammatory cytokines and chemokines in Trex1−/− rats (Fig. 4F). These data together suggest that the pancreas of Trex1−/− rats exhibits IFN-related gene signature, which potentially contributes to the development of diabetes.
Trex1-deficient rats develop diabetic cataracts and diabetic nephropathy
Diabetic patients are usually burdened with different complications, such as diabetic cataracts, peripheral neuropathy and diabetic nephropathy [36, 37]. We therefore determined whether Trex1−/− rats developed similar complications in addition to diabetic phenotype. We noticed that after onset of diabetes, lens of the Trex1−/− rats developed a cloudy and white appearance, resembling the manifestation of diabetic cataracts (DC) in human (Fig. 5A). Histological analysis revealed that the cytoarchitecture of lens in Trex1−/− rats showed disordered arrangement and the cortical fiber cells displayed a number of vacuoles (Fig. 5B). We next performed the slit-lamp examination to assess the progression of diabetic cataracts in Trex1−/− rats. The turbidity levels of lens were graded into six stages by professional ophthalmologists (Additional file 5: Fig. S4A). Our data showed that Trex1−/− rats gradually developed cataract since the onset of diabetes, with mature cataract formation by 9 weeks after diagnosis (Fig. 5C, D). These findings strongly suggest that Trex1−/− rats develop diabetic cataracts after onset of diabetes.
Diabetic nephropathy, one of the most common chronic diabetic complications, is characterized by both functional and structural changes, including albuminuria, glomerulosclerosis, mesangial expansion and tubulointerstitial fibrosis [38, 39]. We observed elevated levels of albuminuria, creatinine and urea in Trex1−/− rats after onset of diabetes, compared to those of WT rats (Fig. 5E, F and Additional file 5: Fig. S4B). We also found the levels of creatinine and urea in serum of Trex1−/− rats increased along time after onset of diabetes (Fig. 5F), suggesting the occurrence and progression of renal damage along disease course. Additionally, histopathological changes were analyzed by periodic acid-Schiff (PAS) staining and Masson trichrome staining. Thickening glomerular basement membrane (GBM), expansive mesangial matrix and renal fibrosis were observed in the kidney of diabetic Trex1−/− rats (Fig. 5G, H). Moreover, the Trex1−/− rats also displayed obvious pathological changes in the tubulointerstitial, such as the loss of tubular cells and tubulointerstitial fibrosis (Additional file 5: Fig. S4C). Further examination uncovered enhanced infiltration of CD68-positive macrophages in the renal tissues of diabetic Trex1−/− rats (Additional file 5: Fig. S4D, E), supporting the conclusion that Trex1−/− rats develop diabetic nephropathy after onset of diabetes.
Discussion
TREX1, as a DNA-degrading enzyme, is closely associated with DNA-sensing mediated innate immune signaling and development of several autoimmune diseases. In this study, we discovered that Trex1−/− rats exhibit high levels of blood glucose, together with insufficient insulin secretion, indicating these rats spontaneously develop T1D. Trex1−/− rats also gradually develop diabetic complications, such as cataracts and nephropathy, after onset of diabetes. Our study thus provides a potential diabetes model which may contribute to exploring the pathogenesis of T1D.
Diabetic animal models are of great significance for investigations of pathogenic mechanisms and development of therapeutic strategies. Although several animal models, including NOD mice, BB rats and STZ-induced diabetic model, have been widely employed in diabetes research, there still remain some limitations. For example, BB rats develop lymphopenia in addition to diabetic phenotype, which differs from symptoms of diabetes patients [40,41,42]. NOD mice exhibit notable differences in diabetes incidence between males and females [8, 43, 44]. In the present work, we demonstrated that Trex1−/− rats spontaneously develop diabetes starting from 4 weeks of age after birth, with a diabetes incidence of up to 70% by 1 year and no significant differences in diabetes incidence between males and females. Trex1−/− rats also develop diabetic nephropathy and diabetic cataract after the onset of diabetes, which resembles the complications as diabetes patients. The development of these complications in Trex1−/− rats may result from prolonged exposure of hyperglycemia, while the possibility that Trex1 deficiency leads to cell death and functional decline in eye and kidney, thereby contributing to the pathogenesis of nephropathy and cataracts, still could not be excluded.
Growing evidences have indicated an important role for type I IFN in the development of T1D [45,46,47]. It was reported that a remarkable type I IFN gene signature was observed in the islets and peripheral blood of individuals with T1D, which appears before the emergence of autoantibodies [45, 48]. By targeting type I IFN-mediated signaling pathway, such as type I IFN receptor, the occurrence of T1D could be delayed [49]. In addition to this, viral infection is one of the environmental risk factors of T1D, which is usually featured by elevated production of IFN. Our study found an evident accumulation of ssDNA, together with an obvious IFN-related gene signature, in pancreata of Trex1−/− rats. As previous studies suggested that TREX1 deficiency leads to accumulation of intracellular DNA, thereby activating cGAS-mediated DNA-sensing pathway and facilitating production of type I IFN, our study thus provides new evidence for the connection between type I IFN and T1D.
Aberrant activation of cGAS has been implicated in the development of autoimmune diseases such as AGS and SLE, and targeting cGAS is becoming a promising strategy for treatment of such diseases. Further studies are needed to determine whether cGAS activation interprets the role of Trex1 deficiency in T1D. And examinations regarding polymorphisms of TREX1 gene and activation of cGAS in diabetic patients are also needed to support their contribution in the pathogenesis of T1D.
Conclusions
In summary, we found that Trex1 deficiency leads to spontaneous development of T1D in rats, accompanied by complications such as diabetic nephropathy and cataract. Local inflammation in pancreas of Trex1−/− rats may be caused by excessive production of proinflammatory cytokines, including type I IFN, which eventually leads to the decline of pancreatic β cells. This study may provide a new animal model for T1D research and new insights into the pathogenesis of T1D.
Availability of data and materials
All RNA sequencing files were deposited in the NCBI Sequence Read Archive under the BioProject number PRJNA1027006. qPCR primers used in this study are included in Additional file 1: Table S1. Other data presented in this study are available from the corresponding authors on reasonable request.
Abbreviations
- TREX1:
-
Three prime repair exonuclease 1
- SD:
-
Sprague Dawley
- T1D:
-
Type 1 diabetes
- IFN:
-
Interferon
- BB:
-
BioBreeding
- cGAS:
-
Cyclic GMP–AMP synthase
- AGS:
-
Aicardi–Goutières syndrome
- SLE:
-
Systemic lupus erythematosus
- FCL:
-
Familial chilblain lupus
- RVCL:
-
Retinal vasculopathy with cerebral leukodystrophy
- STZ:
-
Streptozotocin
- GTT:
-
Glucose tolerance test
- ITT:
-
Insulin tolerance test
- qPCR:
-
Quantitative PCR
- DEGs:
-
Differentially expressed genes
- GADA:
-
Glutamic acid decarboxylase autoantibodies
- IAA:
-
Insulin autoantibodies
- ICA:
-
Islet cell antibodies
- WT:
-
Wild-type
- HbA1c:
-
Hemoglobin A1c
- H&E:
-
Hematoxylin and eosin
- ISG:
-
Interferon-stimulated gene
- DC:
-
Diabetic cataracts
References
Todd JA. Etiology of type 1 diabetes. Immunity. 2010;32(4):457–67.
Noble JA, Valdes AM, Varney MD, Carlson JA, Moonsamy P, Fear AL, et al. HLA class I and genetic susceptibility to type 1 diabetes: results from the Type 1 Diabetes Genetics Consortium. Diabetes. 2010;59(11):2972–9.
Op de Beeck A, Eizirik DL. Viral infections in type 1 diabetes mellitus—why the beta cells? Nat Rev Endocrinol. 2016;12(5):263–73.
Hull CM, Peakman M, Tree TIM. Regulatory T cell dysfunction in type 1 diabetes: what’s broken and how can we fix it? Diabetologia. 2017;60(10):1839–50.
Eizirik DL, Colli ML. Revisiting the role of inflammation in the loss of pancreatic beta-cells in T1DM. Nat Rev Endocrinol. 2020;16(11):611–2.
Bluestone JA, Buckner JH, Herold KC. Immunotherapy: Building a bridge to a cure for type 1 diabetes. Science. 2021;373(6554):510–6.
Alba A, Puertas MC, Carrillo J, Planas R, Ampudia R, Pastor X, et al. IFN beta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes-prone mice. J Immunol. 2004;173(11):6667–75.
Marro BS, Ware BC, Zak J, de la Torre JC, Rosen H, Oldstone MB. Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-alpha signaling. Proc Natl Acad Sci USA. 2017;114(14):3708–13.
Lenzen S, Arndt T, Elsner M, Wedekind D, Jorns A. Rat models of human type 1 diabetes. Methods Mol Biol. 2020;2128:69–85.
Mordes JP, Desemone J, Rossini AA. The BB rat. Diabetes Metab Rev. 1987;3(3):725–50.
Delovitch TL, Singh B. The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity. 1997;7(6):727–38.
Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep. 1963;29:91–8.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50(6):537–46.
Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3′→5′ exonucleases. J Biol Chem. 1999;274(28):19655–60.
Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell. 2007;131(5):873–86.
Gray EE, Treuting PM, Woodward JJ, Stetson DB. Cutting edge: cGAS is required for lethal autoimmune disease in the Trex1-deficient mouse model of Aicardi–Goutieres syndrome. J Immunol. 2015;195(5):1939–43.
Gao D, Li T, Li XD, Chen X, Li QZ, Wight-Carter M, et al. Activation of cyclic GMP–AMP synthase by self-DNA causes autoimmune diseases. Proc Natl Acad Sci USA. 2015;112(42):E5699–705.
Crow YJ, Hayward BE, Parmar R, Robins P, Leitch A, Ali M, et al. Mutations in the gene encoding the 3′–5′ DNA exonuclease TREX1 cause Aicardi–Goutieres syndrome at the AGS1 locus. Nat Genet. 2006;38(8):917–20.
Lee-Kirsch MA, Gong M, Chowdhury D, Senenko L, Engel K, Lee YA, et al. Mutations in the gene encoding the 3′–5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39(9):1065–7.
Rice G, Newman WG, Dean J, Patrick T, Parmar R, Flintoff K, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant Aicardi–Goutieres syndrome. Am J Hum Genet. 2007;80(4):811–5.
Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram P, Spitzer D, et al. C-terminal truncations in human 3′–5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007;39(9):1068–70.
Lee H, Lee YS, Harenda Q, Pietrzak S, Oktay HZ, Schreiber S, et al. Beta cell dedifferentiation induced by IRE1alpha deletion prevents type 1 diabetes. Cell Metab. 2020;31(4):822-36 e5.
Kim H, Perovanovic J, Shakya A, Shen Z, German CN, Ibarra A, et al. Targeting transcriptional coregulator OCA-B/Pou2af1 blocks activated autoreactive T cells in the pancreas and type 1 diabetes. J Exp Med. 2021;218(3):e20200533.
Qaisar N, Lin S, Ryan G, Yang C, Oikemus SR, Brodsky MH, et al. A Critical role for the type I interferon receptor in virus-induced autoimmune diabetes in rats. Diabetes. 2017;66(1):145–57.
Deeds MC, Anderson JM, Armstrong AS, Gastineau DA, Hiddinga HJ, Jahangir A, et al. Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab Anim. 2011;45(3):131–40.
Chen Q, Xiao Z, Wang C, Chen G, Zhang Y, Zhang X, et al. Microneedle patches loaded with nanovesicles for glucose transporter-mediated insulin delivery. ACS Nano. 2022;16(11):18223–31.
Perry RJ, Peng L, Abulizi A, Kennedy L, Cline GW, Shulman GI. Mechanism for leptin’s acute insulin-independent effect to reverse diabetic ketoacidosis. J Clin Invest. 2017;127(2):657–69.
Powers AC. Type 1 diabetes mellitus: much progress, many opportunities. J Clin Invest. 2021;131(8):e142242.
Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787–94.
American Diabetes A. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S13–28.
Eizirik DL, Pasquali L, Cnop M. Pancreatic beta-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol. 2020;16(7):349–62.
Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5(4):219–26.
Ilonen J, Lempainen J, Veijola R. The heterogeneous pathogenesis of type 1 diabetes mellitus. Nat Rev Endocrinol. 2019;15(11):635–50.
Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134(4):587–98.
Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science. 2013;339(6121):786–91.
Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377–90.
Vartak T, Godson C, Brennan E. Therapeutic potential of pro-resolving mediators in diabetic kidney disease. Adv Drug Deliv Rev. 2021;178:113965.
Oshima M, Shimizu M, Yamanouchi M, Toyama T, Hara A, Furuichi K, et al. Trajectories of kidney function in diabetes: a clinicopathological update. Nat Rev Nephrol. 2021;17(11):740–50.
Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K. Molecular pathways that drive diabetic kidney disease. J Clin Invest. 2023;133(4):e165654.
Elder ME, Maclaren NK. Identification of profound peripheral T lymphocyte immunodeficiencies in the spontaneously diabetic BB rat. J Immunol. 1983;130(4):1723–31.
MacMurray AJ, Moralejo DH, Kwitek AE, Rutledge EA, Van Yserloo B, Gohlke P, et al. Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene. Genome Res. 2002;12(7):1029–39.
Yale JF, Grose M, Marliss EB. Time course of the lymphopenia in BB rats. Relation to the onset of diabetes. Diabetes. 1985;34(10):955–9.
Makino S, Kunimoto K, Muraoka Y, Katagiri K. Effect of castration on the appearance of diabetes in NOD mouse. Jikken Dobutsu. 1981;30(2):137–40.
Jansen A, Homo-Delarche F, Hooijkaas H, Leenen PJ, Dardenne M, Drexhage HA. Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and beta-cell destruction in NOD mice. Diabetes. 1994;43(5):667–75.
Apaolaza PS, Balcacean D, Zapardiel-Gonzalo J, Nelson G, Lenchik N, Akhbari P, et al. Islet expression of type I interferon response sensors is associated with immune infiltration and viral infection in type 1 diabetes. Sci Adv. 2021;7(9):eabd6527.
Rodrigues KB, Dufort MJ, Llibre A, Speake C, Rahman MJ, Bondet V, et al. Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes. Diabetologia. 2020;63(8):1576–87.
Lundberg M, Krogvold L, Kuric E, Dahl-Jorgensen K, Skog O. Expression of interferon-stimulated genes in insulitic pancreatic islets of patients recently diagnosed with type 1 diabetes. Diabetes. 2016;65(10):3104–10.
Ferreira RC, Guo H, Coulson RM, Smyth DJ, Pekalski ML, Burren OS, et al. A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes. 2014;63(7):2538–50.
Dos Santos RS, Marroqui L, Velayos T, Olazagoitia-Garmendia A, Jauregi-Miguel A, Castellanos-Rubio A, et al. DEXI, a candidate gene for type 1 diabetes, modulates rat and human pancreatic beta cell inflammation via regulation of the type I IFN/STAT signalling pathway. Diabetologia. 2019;62(3):459–72.
Acknowledgements
Not applicable.
Funding
This work was supported by the National Natural Science Foundation of China (81925017 to TL).
Author information
Authors and Affiliations
Contributions
TZ and WX supervised the project. TZ, WX, TL and J-MZ designed the experiments. XL and MW established the Trex1−/− rats. J-MZ performed the long-term monitoring of blood glucose, the histological and immunofluorescent staining. XL, MW and S-YH performed GTT and ITT. X-YC and X-WL performed the biochemical assays. Z-HS and Z-LG performed ELISA and qPCR analysis. SJ and JP analyzed the RNA-seq data. Z-HS, Q-YH and JC contributed to preparations of tissue samples. JL contributed to the cataract analysis and provided technical support. TZ, WX, TL and J-MZ analyzed the data and drafted the manuscript. All authors approved the submitted version of manuscript.
Corresponding authors
Ethics declarations
Ethics approval and consent to participate
All animal experiments were performed with the approval of the Institutional Animal Care and Use Committee of the National Center of Biomedical Analysis, Beijing, China. The study was conducted in accordance with the local legislation and institutional requirements.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Additional file 1: Table S1.
List of qPCR primer sequences.
Additional file 2: Fig. S1.
Trex1-deficient rats display diabetic-like symptoms. (A) Schematic drawing of Trex1 gene of rat, red arrowhead indicates the sgRNA target sites. (B) The Trex1 gene of WT or Trex1−/− rats was detected by PCR. The smaller PCR products amplified in Trex1−/− rats reflect deletions with CRISPR-Cas9 system. (C) The mRNA expression of Trex1 in indicated tissues from WT or Trex1−/− rats (n=3 per group) was analyzed by qPCR. (D) The water and food intake in WT (n=11) and Trex1−/− (n=13) rats was monitored for 24 hours. (E) Incidence of diabetes in Trex1−/− female (n=26) and Trex1−/− male (n=20) rats from 4 weeks postnatal until 48 weeks. All data are represented as mean ± SEM; Each dot represents independent biological replicate; Unpaired t-test in (C); Mann Whitney test in (D, Food intake); Welch’s t test in (D, Fluid intake); Log-rank (Mantel-Cox) test in (E).
Additional file 3: Fig. S2.
Serum ICA levels and insulitis scoring. (A) Serum ICA levels were measured by Elisa in WT (n=8) and Trex1−/− (n=8) rats. (B) Representative H&E images of the stages of insulitis. Scale bar, 100 μm. All data are represented as mean ± SEM; Welch’s t test in (A).
Additional file 4: Fig. S3.
RNA-seq analysis of the pancreas from WT or Trex1−/− rats. (A) The RNA integrity number values of RNA-seq samples. (B) Volcano plots of significantly differentially expressed genes of the RNA-seq data from pancreas of WT and Trex1−/− rats (n=3 per group). Red, down-regulated; Green, up-regulated. (C) KEGG analysis of down-regulated genes (Trex1−/− vs. WT) in pancreas RNA-seq data set.
Additional file 5: Fig. S4.
Trex1 deficiency leads to the development of diabetic cataract and diabetic nephropathy in rats. (A) Representative slit-lamp photos of the grading of diabetic cataract. (B) The UACR levels were calculated by the ratio of urinary albumin and creatinine in Trex1−/− rats at 8 or 12 weeks after the onset of diabetes (n=3 in each condition). (C) Representative images of kidney tubules from WT or Trex1−/− rats stained by PAS or Masson’s trichrome. Scale bar, 40 μm. (D) Representative fluorescence images of kidney sections from WT or Trex1−/− rats stained with CD68 (red) antibody. The cell nuclei were stained with Hoechst (blue). Scale bar, 20 μm. (E) The number of CD68+ cells in kidney from WT (n=3) or Trex1−/− (n=3) rats were quantified. 10 glomeruli were analyzed in each of the rats. Data are represented as mean ± SEM; Each dot represents independent biological replicate; Unpaired t-test in (B UACR 8 w, UACR 8 w and 12 w); Welch’s t test in (B UACR 12 w, E).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Zhao, JM., Su, ZH., Han, QY. et al. Deficiency of Trex1 leads to spontaneous development of type 1 diabetes. Nutr Metab (Lond) 21, 2 (2024). https://doi.org/10.1186/s12986-023-00777-6
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12986-023-00777-6